Banco Santander, S.A.

Banco Santander, S.A. Earnings Recaps

SAN Financials 2 recaps
Next earnings: February 2, 2027 (estimated) · full calendar
Q3 2026 Nov 2, 2026

Santander shares fell 5.8% after earnings, despite growth in profit and revenue. The transcript offers no explicit guidance cut or clear explanation for the selloff; Argentina-related loan-loss provisions and the outlook for EV incentives are potential pressure points, but neither is identified as the cause of the market reaction.

Key takeaways
  • Underlying profit for the first nine months reached a record €11.2 billion, up 14% year on year in constant euros.
  • Revenue rose 7%, with net interest income up 8% and fees up 7%; costs declined excluding TSB and Webster.
  • Efficiency improved by almost 2 percentage points, while underlying RoTE rose to 16% and CET1 stood at 12.7%.
  • Loan-loss provisions remained affected by Argentina; Santander said provisions in the rest of the group grew broadly in line with organic portfolio growth.
  • In the U.S., profit was up 24% year on year excluding Webster, while the transcript also noted that U.S. electric-vehicle tax incentives had ended.
Q3 2025 Oct 29, 2025

Santander achieved a record quarterly profit of EUR 3.5 billion in Q3 2025, reflecting robust revenue growth and a strategic focus on efficiency amid a challenging environment.

Key takeaways
  • Strong revenue growth of 4% in constant euros, driven by net interest income and a record 8% increase in fees.
  • Return on Tangible Equity (RoTE) improved by 70 basis points to 16.1%, on track to reach a post-AT1 target of around 16.5%.
  • Total customer base grew to 178 million, up 7 million year-on-year, enhancing overall customer engagement and experience.
  • Continued focus on digitalization and operational efficiency, with significant reductions in costs and a 17% decrease in non-commercial team activities.
  • Shareholder value creation through an accelerated EUR 10 billion share buyback program planned for 2025-2026, subject to regulatory approvals.